Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 2,840 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Niraparib, Dostarlimab, Radiation therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Durham, North Carolina + 1 more
Conditions
Breast Cancer
Interventions
Bevacizumab, Docetaxel, Trastuzumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Melanoma
Interventions
LOC-paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma
Interventions
TLN-232
Drug
Lead sponsor
Thallion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
Interventions
ASSIST phone application
Other
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Capecitabine, Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Interventions
Bemcentinib; pembrolizumab
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Duarte, California • San Diego, California • Kansas City, Missouri + 2 more
Conditions
Breast Cancer
Interventions
E7389, Physician's Choice
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Gilroy, California + 29 more
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Breast Cancer
Interventions
PET Imaging With Cu-64 Labeled Trastuzumab
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Breast, Breast Cancer
Interventions
pegfilgrastim
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2041
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Breast Neoplasms
Interventions
XL147 (SAR245408), trastuzumab, paclitaxel
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Fort Meyers, Florida • Boston, Massachusetts + 4 more
Conditions
Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
Interventions
Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic HR+/HER2- Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Valemetostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Houston, Texas
Terminated Not applicable Interventional Results available

Quell Opioid Reduction and Pain Relief in Patients With Cancer

NCT02809846
Conditions
Pain, Metastatic Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
Quell, Sham Quell
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Conditions
Metastatic Cancer, Melanoma
Interventions
Vemurafenib, Young TIL, Cyclophosphamide, Fludarabine, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma
Interventions
Vemurafenib and Trientine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Cancer, Solid Tumor, Cancer of Skin
Interventions
2141 V-11
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
docetaxel, fluorouracil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
6
States / cities
Goldsboro, North Carolina • Greenville, North Carolina • Winston-Salem, North Carolina + 3 more
Conditions
Breast Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Conditions
Unresectable or Metastatic Melanoma
Interventions
BMS-936558, Dacarbazine, Carboplatin, Paclitaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
32
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Conditions
Metastatic Breast Cancer, Lung Cancer
Interventions
Dichloroacetate (DCA)
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California